吡柔比星及多西他赛联合新辅助化疗在年轻乳腺癌患者中的应用效果

摘要
图/表
参考文献(15)
相关文章 (15)

全文: PDF (443 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨吡柔比星及多西他赛联合新辅助化疗在年轻乳腺癌患者中的疗效及对患者预后、癌组织增殖细胞核抗原Ki-67（Ki-67）、人表皮生长因子受体（Her-2）、血管内皮生长因子（VEGF）表达的影响。方法选取2015年1月至2017年8月铁岭市中心医院收治的90 例年轻乳腺癌患者作为研究对象。采用电脑随机数字表法将其分为联合组和对照组，每组各45 例。对照组患者采用多西他赛化疗，联合组患者则采用吡柔比星及多西他赛联合新辅助化疗。比较两组患者的临床疗效；比较两组患者治疗前后的Ki-67、Her-2、VEGF 表达情况以及T 淋巴细胞亚群（CD3+、CD4+、CD8+、CD4+/CD8+）水平；比较两组患者的预后情况[3年无瘤生存率（DFS）、总生存期（OS）]。结果联合组患者的近期治疗总有效率高于对照组，差异有统计学意义（P＜0.05）。联合组患者治疗后的Ki-67 及VEGF 阳性率分别为22.22%、37.78%，均低于对照组的51.11%、62.22%，差异有统计学意义（P＜0.05）；两组患者治疗后的Her-2 阳性率比较，差异无统计学意义（P＞0.05）。联合组患者的3年DFS 及OS 分别为93.33%、97.78%，均高于对照组的73.33%、82.22%，差异有统计学意义（P＜0.05）。两组患者治疗前的各项T 淋巴细胞亚群指标水平比较，差异无统计学意义（P＞0.05）；两组患者治疗后的CD3+、CD4+、CD4+/CD8+低于治疗前，CD8+水平高于治疗前，差异有统计学意义（P＜0.05）；联合组患者治疗后的CD3+、CD4+、CD4+/CD8+高于对照组，CD8+水平低于对照组，差异有统计学意义（P＜0.05）。结论吡柔比星及多西他赛联合新辅助化疗应用于年轻乳腺癌患者中，可获得较为理想的近期疗效以及预后，同时可在一定程度上降低Ki-67、VEGF 表达水平，增强机体免疫功能。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	曹丹

关键词 ：乳腺癌, 吡柔比星, 多西他赛, 新辅助化疗, 肿瘤标志物

Abstract：Objective To investigate the efficacy of Pyrorubicin and Docetaxel combined with neoadjuvant chemotherapy in young breast cancer,and the effect on prognosis,expression of cancer tissue proliferative nuclear antigen Ki-67(Ki-67),human epidermal growth factor receptor(Her-2)and vascular endothelial growth factor(VEGF)in cancer tissues.Methods A total of 90 young breast cancer patients admitted to Tieling Central Hospital from January 2015 to August 2017 were selected as research subjects.They were divided into combined group and control group by computer random number table method,with 45 cases in each group.The control group received Docetaxel chemotherapy,while the combined group received Pyrorubicin and Docetaxel combined with neoadjuvant chemotherapy.The clinical efficacy of the two groups was compared.The expressions of Ki-67,Her-2,VEGF and the levels of T lymphocyte subsets (CD3+,CD4+,CD8+,CD4+/CD8+) of patients in the two groups before and after treatment were compared.The prognosis (3-year disease-free survival rate [DFS],overall survival period [OS]) of patients in the two groups was compared.Results The total effective rate in combined group was higher than that in control group,the difference was statistically significant(P＜0.05).The positive rates of Ki-67 and VEGF in the combined group were 22.22% and 37.78%,respectively,lower than 51.11% and 62.22% in the control group,with statistical significances (P＜0.05).There was no significant difference in the positive rate of Her-2 between the two groups after treatment (P＞0.05).The 3-year DFS and OS of the combined group were 93.33% and 97.78%,respectively,which were higher than those of the control group of 73.33%and 82.22%,respectively,the differences were statistically significant (P＜0.05).There were no significant differences in the levels of various T lymphocyte subsets before treatment between the two groups (P＞0.05).After treatment,CD3+,CD4+,CD4+/CD8+ were lower than those before treatment,while CD8+ level was higher than that before treatment,the differences were statistically significant (P＜0.05).After treatment,CD3+,CD4+and CD4+/CD8+in combined group were higher than those in control group,while CD8+ was lower than that in control group,the differences were statistically significant (P＜0.05).Conclusions The Pyrorubicin and Docetaxel combined with neoadjuvant chemotherapy in young breast cancer patients can achieve ideal short-term efficacy and prognosis,and can reduce the expression levels of Ki-67 and VEGF to a certain extent,and enhance the immune function of the body.

Key words： Breast cancer Pyrorubicin Docetaxel Neoadjuvant chemotherapy Tumor marker

引用本文:

曹丹. 吡柔比星及多西他赛联合新辅助化疗在年轻乳腺癌患者中的应用效果[J]. 中国当代医药, 2022, 29(3): 82-85.
CAO Dan. Application effect of Pyrorubicin and Docetaxel combined with neoadjuvant chemotherapy in young breast cancer patients. 中国当代医药, 2022, 29(3): 82-85.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2022/V29/I3/82

[1]	郭宁，李彩霞，朱德淼，等.华蟾素胶囊联合吡柔比星治疗晚期乳腺癌的临床研究[J].现代药物与临床，2019，34（1）：200-204.
[2]	周凤英，张萍，陆肖玮，等.环磷酰胺、阿霉素联合多西他赛用于乳腺癌化疗的疗效观察[J].实用临床医药杂志，2017，21（21）：184-186.
[3]	段奇，杨颖涛，杨青，等.可溶性ST-2 对接受阿霉素化疗乳腺癌患者的左心功能及结构变化预测价值的研究[J].中国普外基础与临床杂志，2020，27（2）：147-151.
[4]	安雪青，吕健东，苏锋，等.薄芝糖肽注射液联合吡柔比星和多西他赛治疗乳腺癌的临床研究[J].现代药物与临床，2018，33（1）：114-118.
[5]	王燕，张平洋，刘琨，等.三维斑点追踪成像技术评价乳腺癌患者接受吡柔比星化疗后右心室心肌力学特性改变[J].南方医科大学学报，2018，38（9）：1032-1038.
[6]	中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范（2019年版）[J].中国癌症杂志，2019，29（8）：609-679.
[7]	罗恩茜，倪青.乳腺癌不同方案新辅助化疗后对粒细胞减少的影响及处理[J].重庆医学，2018，47（7）：971-974.
[8]	黄恒，揭超，崔杉，等.多西他赛加吡柔比星用于中晚期乳腺癌新辅助化疗的临床研究[J].实用医学杂志，2009，25（8）：1315-1316.
[9]	徐璐，陈峙霖.多西他赛联合吡柔比星用于乳腺癌保乳术后辅助化疗疗效及安全性分析[J].中国药业，2019，28（2）：67-70.
[10]	王孝伟，郑默然，张玉英，等.吡柔比星联合多西他赛新辅助化疗对年轻女性乳腺癌患者临床疗效和癌组织中肿瘤增殖相关因子表达情况的影响[J].中国医药，2021，16（2）：250-253.
[11]	张萌萌，洛菲.蒽环类药物治疗乳腺癌的心血管风险及对策[J].肿瘤研究与临床，2018，30（3）：173-175.
[12]	郑向欣，吴骥，顾书成，等.TP 与FAC 辅助化疗对原发灶分子分型Luminal A 伴有腋淋巴结转移灶三阴性乳腺癌患者的效果影响[J].中国综合临床，2018，34（6）：524-527.
[13]	单昌友，刁岩，黄珊，等.槐耳颗粒联合新辅助化疗对乳腺癌的疗效及对P53、Ki-67、MMP-2、MMP-9 水平的影响[J].河北医学，2018，24（4）：579-583.
[14]	胡艳玲，李国利，林中翔.血清RASSFlA 和WIF-1 甲基化水平可评估晚期乳腺癌行新辅助化疗疗效[J].基因组学与应用生物学，2018，37（11）：4937-4942.
[15]	张婷，刘起鹏，郭婉莹，等.曲妥珠单抗联合术前新辅助化学治疗对乳腺癌患者肿瘤标志物、血管内皮因子和凋亡因子的影响及疗效观察[J].新乡医学院学报，2020，37（11）：1075-1079.